Ultra-long-term subcutaneous home monitoring of epilepsy

Sigge Weisdorf; Jonas Duun-Henriksen; Marianne J. Kjeldsen; Frantz R. Poulsen; Sirin W. Gangstad; Troels W. Kjær

doi:10.1111/epi.16360

Ultra-long-term subcutaneous home monitoring of epilepsy

Sigge Weisdorf^*, Jonas Duun-Henriksen, Marianne J. Kjeldsen, Frantz R. Poulsen, Sirin W. Gangstad, Troels W. Kjær

^*Corresponding author af dette arbejde

18 Citationer (Scopus)

Abstract

Objective: To explore the feasibility of home monitoring of epilepsy patients with a novel subcutaneous electroencephalography (EEG) device, including clinical implications, safety, and compliance via the first real-life test. Methods: We implanted a beta-version of the 24/7 EEG SubQ (UNEEG Medical A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. Data on seizures, adverse events, compliance in using the device, and use of antiepileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and all EEG data were reviewed visually to identify electrographic seizures. These were descriptively compared to seizure counts and AED changes reported in diaries from the same period. Results: Four hundred ninety days of EEG and 338 electrographic seizures were collected. Eight participants completed at least 9 weeks of home monitoring, while one cancelled participation after 4 weeks due to postimplantation soreness. In total, 13 cases of device-related adverse events were registered, none of them serious. Recordings obtained from the device covered 73% of the time, on average (range 45%-91%). Descriptively, electrographic seizure counts were substantially different from diary seizure counts. We uncovered several cases of underreporting and revealed important information on AED response. Electrographic seizure counts revealed circadian distributions of seizures not visible from seizure diaries. Significance: The study shows that home monitoring for up to 3 months with a subcutaneous EEG device is feasible and well tolerated. No serious adverse device-related events were reported. An objective seizure count can be derived, which often differs substantially from self-reported seizure counts. Larger clinical trials quantifying the benefits of objective seizure counting should be a priority for future research as well as development of algorithms for automated review of data.

Originalsprog	Engelsk
Tidsskrift	Epilepsia
Vol/bind	60
Udgave nummer	11
Sider (fra-til)	2204-2214
ISSN	0013-9580
DOI	https://doi.org/10.1111/epi.16360
Status	Udgivet - 2019

Adgang til dokumentet

10.1111/epi.16360Licens: CC BY-NC

Weisdorf_et_al-2019-EpilepsiaForlagets udgivne version, 1,84 MBLicens: CC BY-NC

Citationsformater

@article{1d43dd3498b9476d8a0968aa6a7d8b61,

title = "Ultra-long-term subcutaneous home monitoring of epilepsy",

abstract = "Objective: To explore the feasibility of home monitoring of epilepsy patients with a novel subcutaneous electroencephalography (EEG) device, including clinical implications, safety, and compliance via the first real-life test. Methods: We implanted a beta-version of the 24/7 EEG SubQ (UNEEG Medical A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. Data on seizures, adverse events, compliance in using the device, and use of antiepileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and all EEG data were reviewed visually to identify electrographic seizures. These were descriptively compared to seizure counts and AED changes reported in diaries from the same period. Results: Four hundred ninety days of EEG and 338 electrographic seizures were collected. Eight participants completed at least 9 weeks of home monitoring, while one cancelled participation after 4 weeks due to postimplantation soreness. In total, 13 cases of device-related adverse events were registered, none of them serious. Recordings obtained from the device covered 73% of the time, on average (range 45%-91%). Descriptively, electrographic seizure counts were substantially different from diary seizure counts. We uncovered several cases of underreporting and revealed important information on AED response. Electrographic seizure counts revealed circadian distributions of seizures not visible from seizure diaries. Significance: The study shows that home monitoring for up to 3 months with a subcutaneous EEG device is feasible and well tolerated. No serious adverse device-related events were reported. An objective seizure count can be derived, which often differs substantially from self-reported seizure counts. Larger clinical trials quantifying the benefits of objective seizure counting should be a priority for future research as well as development of algorithms for automated review of data.",

keywords = "EEG, epilepsy, home monitoring, long-term monitoring, subcutaneous EEG",

author = "Sigge Weisdorf and Jonas Duun-Henriksen and Kjeldsen, {Marianne J.} and Poulsen, {Frantz R.} and Gangstad, {Sirin W.} and Kj{\ae}r, {Troels W.}",

year = "2019",

doi = "10.1111/epi.16360",

language = "English",

volume = "60",

pages = "2204--2214",

journal = "Epilepsia",

issn = "0013-9580",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - Ultra-long-term subcutaneous home monitoring of epilepsy

AU - Weisdorf, Sigge

AU - Duun-Henriksen, Jonas

AU - Kjeldsen, Marianne J.

AU - Poulsen, Frantz R.

AU - Gangstad, Sirin W.

AU - Kjær, Troels W.

PY - 2019

Y1 - 2019

N2 - Objective: To explore the feasibility of home monitoring of epilepsy patients with a novel subcutaneous electroencephalography (EEG) device, including clinical implications, safety, and compliance via the first real-life test. Methods: We implanted a beta-version of the 24/7 EEG SubQ (UNEEG Medical A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. Data on seizures, adverse events, compliance in using the device, and use of antiepileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and all EEG data were reviewed visually to identify electrographic seizures. These were descriptively compared to seizure counts and AED changes reported in diaries from the same period. Results: Four hundred ninety days of EEG and 338 electrographic seizures were collected. Eight participants completed at least 9 weeks of home monitoring, while one cancelled participation after 4 weeks due to postimplantation soreness. In total, 13 cases of device-related adverse events were registered, none of them serious. Recordings obtained from the device covered 73% of the time, on average (range 45%-91%). Descriptively, electrographic seizure counts were substantially different from diary seizure counts. We uncovered several cases of underreporting and revealed important information on AED response. Electrographic seizure counts revealed circadian distributions of seizures not visible from seizure diaries. Significance: The study shows that home monitoring for up to 3 months with a subcutaneous EEG device is feasible and well tolerated. No serious adverse device-related events were reported. An objective seizure count can be derived, which often differs substantially from self-reported seizure counts. Larger clinical trials quantifying the benefits of objective seizure counting should be a priority for future research as well as development of algorithms for automated review of data.

AB - Objective: To explore the feasibility of home monitoring of epilepsy patients with a novel subcutaneous electroencephalography (EEG) device, including clinical implications, safety, and compliance via the first real-life test. Methods: We implanted a beta-version of the 24/7 EEG SubQ (UNEEG Medical A/S, Denmark) subcutaneously in nine participants with temporal lobe epilepsy. Data on seizures, adverse events, compliance in using the device, and use of antiepileptic drugs (AEDs) were collected. EEG was recorded for up to 3 months, and all EEG data were reviewed visually to identify electrographic seizures. These were descriptively compared to seizure counts and AED changes reported in diaries from the same period. Results: Four hundred ninety days of EEG and 338 electrographic seizures were collected. Eight participants completed at least 9 weeks of home monitoring, while one cancelled participation after 4 weeks due to postimplantation soreness. In total, 13 cases of device-related adverse events were registered, none of them serious. Recordings obtained from the device covered 73% of the time, on average (range 45%-91%). Descriptively, electrographic seizure counts were substantially different from diary seizure counts. We uncovered several cases of underreporting and revealed important information on AED response. Electrographic seizure counts revealed circadian distributions of seizures not visible from seizure diaries. Significance: The study shows that home monitoring for up to 3 months with a subcutaneous EEG device is feasible and well tolerated. No serious adverse device-related events were reported. An objective seizure count can be derived, which often differs substantially from self-reported seizure counts. Larger clinical trials quantifying the benefits of objective seizure counting should be a priority for future research as well as development of algorithms for automated review of data.

KW - EEG

KW - epilepsy

KW - home monitoring

KW - long-term monitoring

KW - subcutaneous EEG

U2 - 10.1111/epi.16360

DO - 10.1111/epi.16360

M3 - Journal article

C2 - 31608435

AN - SCOPUS:85074015803

SN - 0013-9580

VL - 60

SP - 2204

EP - 2214

JO - Epilepsia

JF - Epilepsia

IS - 11

ER -

Ultra-long-term subcutaneous home monitoring of epilepsy

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater